Description
ADCC-Enhanced anti-CCR2 (MLN1202) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Antibody Indication
Atherosclerosis; Multiple Sclerosis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CCR2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CCR2
Full Name
chemokine (C-C motif) receptor 2
Background
This gene encodes two isoforms of a receptor for monocyte chemoattractant protein-1, a chemokine which specifically mediates monocyte chemotaxis. Monocyte chemoattractant protein-1 is involved in monocyte infiltration in inflammatory diseases such as rheumatoid arthritis as well as in the inflammatory response against tumors. The receptors encoded by this gene mediate agonist-dependent calcium mobilization and inhibition of adenylyl cyclase. This gene is located in the chemokine receptor gene cluster region. Two alternatively spliced transcript variants are expressed by the gene.
Alternative Names
CCR2; chemokine (C-C motif) receptor 2; CKR2; CCR-2; CCR2A; CCR2B; CD192; CKR2A; CKR2B; CMKBR2; MCP-1-R; CC-CKR-2; MCP-1 receptor; monocyte chemoattractant protein 1 receptor; monocyte chemotactic protein 1 receptor
Gene ID
729230
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with CCR2 include Human Immunodeficiency Virus Type 1 and Idiopathic Anterior Uveitis.
Related Pathways
Its related pathways are Signaling by GPCR and Defensins.
Function
The key functional receptor for CCL2, but it can also bind to CCL7 and CCL12. It binds to CCL2 on monocytes and macrophages, and induces chemotaxis and migration (possibly) by activating the PI3K cascade, small G protein Rac, and plate platform protrusions. It also acts as a receptor for the defensins DEFB106A/DEFB106B. Regulates the expression of T cell inflammatory factors and T cell differentiation, and promotes T cell differentiation into T-helper 17 cells (Th17) (through similarity) during inflammation. Promote the output of mature thymocytes, enhance the directional movement of thymocytes stimulated by sphingosine-1-phosphate and up-regulate S1P1R expression; regulate FOXO1 activity through the JAK-STAT pathway, resulting in increased S1P1R expression (through similarity). Plays an important role in mediating neuropathic pain caused by peripheral nerve injury (similar). The increase in nmda-mediated synaptic transmission in both dopamine D1 and D2 receptor neurons may be caused by MAPK/erk-dependent phosphorylation of GRIN2B/NMDAR2B (similarity). Mediates the aggregation of macrophages and monocytes to the injury site after brain injury (by similarity).
Post-translational modifications
N-glycosylated. Sulfation increases the affinity for both monomeric and dimeric CCL2 with stronger binding to the monomeric form. Binding of sulfated CCR2 to CCL2 promotes conversion of CCL2 from dimer to monomer.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
MLN1202
Description
MLN1202 is a humanized monoclonal antibody with high specificity to CCR2, which interrupts MCP-1 binding to CCR2. MLN1202 is being developed for the treatment of immune mediated diseases.
Antibody Indication
Atherosclerosis; Multiple Sclerosis
Atherosclerosis; Multiple Sclerosis
